Microplastics: The Snowflakes of the Plastic World
Science writer Kerry Taylor-Smith takes a deep dive into the persistent problem of microplastics.
Multidimensional Mass Spectrometry and Machine Learning: A Recipe for Richer Metabolomics
A new metabolomics workflow has been developed that combines state-of-the-art analytical instrumentation, which generates information-rich data, with a novel machine learning-based algorithm tailored to process it.
Separating ELA from the Crowd
Select Biosciences, organizers of European Lab Automation (ELA) 2011, announces that the inaugural Advances in Separation Technology (AST) conference will form one of the ten conference streams at ELA.
Bringing Automation into Biobanks
Select Biosciences, organizers of European Lab Automation (ELA) 2011, announces that the World Biobanking Summit will join the highly topical conference streams already confirmed at this unique laboratory automation conference and exhibition.
New Life Science Awards Event Precedes ELA 2011
Select Biosciences and co-organisers, Langton Howarth, announce that the inaugural Life Science Awards will be held on the evening of 29 June at the Radisson Blu Hotel, Hamburg, Germany.
The conference agendas for ADMET Europe, MedChem Europe, Pharma Outsourcing Congress and Flow Chemistry Europe to be held 28-29 March, 2011 in Munich, Germany have now been released.
The conference agendas for Advances in qPCR, RNAi & miRNA World Congress, Epigenetics World Congress and Next-Gen Sequencing Congress to be held 26-27 April, 2011 in Boston, MA, USA have now been released.
Fast growth MAb market to offer great rewards to a select few over 2009-15
Datamonitor predicts that the MAb sector will record a near double-digit growth rate over 2009-15, making it the fastest growing molecule type segment in the prescription pharmaceutical industry. With total sales derived by a select band of blockbuster products, the MAb sector is a tough market to break in to, but one that offers high rewards.
Cytheris Initiates INSPIRE 3, a Phase II Clinical Trial of CYT107 in Chronically Infected HIV Patients
Phase II clinical program will evaluate the effect of repeated cycles of the company’s investigative immune-modulator in the treatment of Immunological Non-Responders.